Patents by Inventor Yeong-Mun Kim

Yeong-Mun Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210009720
    Abstract: The present invention relates to an immunocytokine in which a human interferon-beta variant is conjugated to an antibody or a fragment thereof, and a method for preparing the same.
    Type: Application
    Filed: September 16, 2020
    Publication date: January 14, 2021
    Inventors: Young Kee SHIN, Young Deug KIM, Jun Young CHOI, Tae Eun KIM, Young Jin LEE, Ju Ho LEE, Yeong Mun KIM
  • Patent number: 10806799
    Abstract: The present invention relates to an immunocytokine in which a human interferon-beta variant is conjugated to an antibody or a fragment thereof, and a method for preparing the same. The human interferon-beta variant has superior activity or functions compared with natural interferon-beta, and the productivity of the immunocytokine according to the present invention is excellent. In addition, the immunocytokine according to the present invention can be favorably used as a target therapeutic agent for multiple sclerosis or cancer since the immunocytokine express both of functions of the interferon-beta and characteristics of the antibody binding to a specific antigen.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: October 20, 2020
    Assignee: GENOPHARM INC.
    Inventors: Young Kee Shin, Young Deug Kim, Jun Young Choi, Tae Eun Kim, Young Jin Lee, Ju Ho Lee, Yeong Mun Kim
  • Patent number: 10576846
    Abstract: A release actuator for a vehicle seat includes a spur gear that is rotatable in one direction or in the other direction by receiving rotational force from a motor, and has sliding grooves that are formed in both surfaces of the spur gear and have a predetermined length. A first cable guide is disposed to face one surface of the spur gear and has a protrusion placed in one of the sliding grooves. The first cable guide is connected to a first cable that withdraws a walk-in latch and releases walk-in lock when the first cable is pulled. A second cable guide is disposed to face the other surface of the spur gear, has a protrusion placed in the other sliding groove, and is connected to a second cable that withdraws a folder lock latch and releases folder lock when the second cable is pulled.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: March 3, 2020
    Assignees: Hyundai Motor Company, Daedong Movel System Co., Ltd., Das Co., Ltd.
    Inventors: Sang-Soo Lee, Tae-Jun Kwon, Young-Dong Kim, Sang-Ho Kim, Young-Bok Sung, Ji-Hyong Lee, Jae-Hwa Lee, Seong-Mun Ju, Yeong-Sik Joo, Myoung-Soo Chang, Yun-Soo Kim
  • Patent number: 10179132
    Abstract: Disclosed is a composition for inducing the differentiation of neural stem cells into dopaminergic neurons. The composition includes the compound represented by Formula 1 (“AS703026”) as a MEK 1/2 inhibitor. Also disclosed is a method for inducing the differentiation of neural stem cells into dopaminergic neurons by using the composition. Dopaminergic neurons whose differentiation from neural stem cells is induced by the composition and method can be applied to cell replacement therapies and gene therapies for the treatment of neurodegenerative diseases, such as Parkinson's disease, or can be widely used as materials for the examination of drug effects or numerous studies in the development of new drugs.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: January 15, 2019
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell Choi, Mi-Yeon Kim, Yeong-Mun Kim
  • Publication number: 20180236092
    Abstract: The present invention relates to an immunocytokine in which a human interferon-beta variant is conjugated to an antibody or a fragment thereof, and a method for preparing the same. The human interferon-beta variant has superior activity or functions compared with natural interferon-beta, and the productivity of the immunocytokine according to the present invention is excellent. In addition, the immunocytokine according to the present invention can be favorably used as a target therapeutic agent for multiple sclerosis or cancer since the immunocytokine express both of functions of the interferon-beta and characteristics of the antibody binding to a specific antigen.
    Type: Application
    Filed: August 31, 2017
    Publication date: August 23, 2018
    Inventors: Young Kee SHIN, Young Deug Kim, Jun Young Choi, Tae Eun Kim, Young Jin Lee, Jun Ho Lee, Yeong Mun Kim
  • Publication number: 20170209451
    Abstract: Disclosed is a composition for inducing the differentiation of neural stem cells into dopaminergic neurons. The composition includes the compound represented by Formula 1 (“AS703026”) as a MEK 1/2 inhibitor. Also disclosed is a method for inducing the differentiation of neural stem cells into dopaminergic neurons by using the composition. Dopaminergic neurons whose differentiation from neural stem cells is induced by the composition and method can be applied to cell replacement therapies and gene therapies for the treatment of neurodegenerative diseases, such as Parkinson's disease, or can be widely used as materials for the examination of drug effects or numerous studies in the development of new drugs.
    Type: Application
    Filed: March 10, 2017
    Publication date: July 27, 2017
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell CHOI, Mi-Yeon KIM, Yeong-Mun KIM
  • Publication number: 20160346329
    Abstract: Disclosed is a composition for inducing the differentiation of neural stem cells into dopaminergic neurons. The composition includes the compound represented by Formula 1 (“AS703026”) as a MEK 1/2 inhibitor. Also disclosed is a method for inducing the differentiation of neural stem cells into dopaminergic neurons by using the composition. Dopaminergic neurons whose differentiation from neural stem cells is induced by the composition and method can be applied to cell replacement therapies and gene therapies for the treatment of neurodegenerative diseases, such as Parkinson's disease, or can be widely used as materials for the examination of drug effects or numerous studies in the development of new drugs.
    Type: Application
    Filed: October 7, 2015
    Publication date: December 1, 2016
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell CHOI, Mi-Yeon Kim, Yeong-Mun Kim